Your browser doesn't support javascript.
loading
B cell receptor repertoire analysis from autopsy samples of COVID-19 patients.
Iwabuchi, Sadahiro; Tsukahara, Tomohide; Okayama, Toshitugu; Kitabatake, Masahiro; Motobayashi, Hideki; Shichino, Shigeyuki; Imafuku, Tadashi; Yamaji, Kenzaburo; Miyamoto, Kyohei; Tamura, Shinobu; Ueha, Satoshi; Ito, Toshihiro; Murata, Shin-Ichi; Kondo, Toshikazu; Ikeo, Kazuho; Suzuki, Yutaka; Matsushima, Kouji; Kohara, Michinori; Torigoe, Toshihiko; Yamaue, Hiroki; Hashimoto, Shinichi.
Afiliación
  • Iwabuchi S; Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
  • Tsukahara T; Department of Pathology, Sapporo Medical University School of Medicine, Hokkaido, Japan.
  • Okayama T; Laboratory of DNA Data Analysis, National Institute of Genetics, Shizuoka, Japan.
  • Kitabatake M; Department of Immunology, Nara Medical University, Nara, Japan.
  • Motobayashi H; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
  • Shichino S; Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
  • Imafuku T; Department of Molecular Pathophysiology, Institute of Advanced Medicine, Wakayama Medical University, Wakayama, Japan.
  • Yamaji K; Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Miyamoto K; Department of Emergency and Critical Care Medicine, Wakayama Medical University, Wakayama, Japan.
  • Tamura S; Department of Emergency and Critical Care Medicine, Wakayama Medical University, Wakayama, Japan.
  • Ueha S; Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
  • Ito T; Department of Immunology, Nara Medical University, Nara, Japan.
  • Murata SI; Departments of Human Pathology, Wakayama Medical University, Wakayama, Japan.
  • Kondo T; Department of Forensic Medicine, Wakayama Medical University, Wakayama, Japan.
  • Ikeo K; Laboratory of DNA Data Analysis, National Institute of Genetics, Shizuoka, Japan.
  • Suzuki Y; Department of Computational Biology, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
  • Matsushima K; Division of Molecular Regulation of Inflammatory and Immune Disease, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
  • Kohara M; Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Torigoe T; Department of Pathology, Sapporo Medical University School of Medicine, Hokkaido, Japan.
  • Yamaue H; Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
  • Hashimoto S; Departments of Cancer Immunology, Wakayama Medical University, Wakayama, Japan.
Front Immunol ; 14: 1034978, 2023.
Article en En | MEDLINE | ID: mdl-36911681
Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being developed world over. We investigated the possibility of producing artificial antibodies from the formalin fixation and paraffin-embedding (FFPE) lung lobes of a patient who died by coronavirus disease 2019 (COVID-19). The B-cell receptors repertoire in the lung tissue where SARS-CoV-2 was detected were considered to have highly sensitive virus-neutralizing activity, and artificial antibodies were produced by combining the most frequently detected heavy and light chains. Some neutralizing effects against the SARS-CoV-2 were observed, and mixing two different artificial antibodies had a higher tendency to suppress the virus. The neutralizing effects were similar to the immunoglobulin G obtained from healthy donors who had received a COVID-19 mRNA vaccine. Therefore, the use of FFPE lung tissue, which preserves the condition of direct virus sensitization, to generate artificial antibodies may be useful against future unknown infectious diseases.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Japón